DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $33.49 billion. The enterprise value is $32.95 billion.
| Market Cap | 33.49B |
| Enterprise Value | 32.95B |
Important Dates
The last earnings date was Thursday, July 30, 2026, after market close.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 377.36 million shares outstanding. The number of shares has decreased by -2.61% in one year.
| Current Share Class | 377.36M |
| Shares Outstanding | 377.36M |
| Shares Change (YoY) | -2.61% |
| Shares Change (QoQ) | -0.89% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 104.64% |
| Float | 375.96M |
Valuation Ratios
The trailing PE ratio is 35.00 and the forward PE ratio is 31.57. DexCom's PEG ratio is 1.49.
| PE Ratio | 35.00 |
| Forward PE | 31.57 |
| PS Ratio | 6.74 |
| Forward PS | 6.09 |
| PB Ratio | 12.78 |
| P/TBV Ratio | 13.42 |
| P/FCF Ratio | 23.84 |
| P/OCF Ratio | 19.15 |
| PEG Ratio | 1.49 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.48, with an EV/FCF ratio of 23.45.
| EV / Earnings | 32.96 |
| EV / Sales | 6.63 |
| EV / EBITDA | 23.48 |
| EV / EBIT | 28.92 |
| EV / FCF | 23.45 |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.53.
| Current Ratio | 1.73 |
| Quick Ratio | 1.37 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | 0.97 |
| Debt / FCF | 1.00 |
| Interest Coverage | 75.94 |
Financial Efficiency
Return on equity (ROE) is 38.49% and return on invested capital (ROIC) is 44.49%.
| Return on Equity (ROE) | 38.49% |
| Return on Assets (ROA) | 10.33% |
| Return on Invested Capital (ROIC) | 44.49% |
| Return on Capital Employed (ROCE) | 27.80% |
| Weighted Average Cost of Capital (WACC) | 11.56% |
| Revenue Per Employee | $447,676 |
| Profits Per Employee | $90,063 |
| Employee Count | 11,100 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 2.88 |
Taxes
In the past 12 months, DexCom has paid $280.30 million in taxes.
| Income Tax | 280.30M |
| Effective Tax Rate | 21.90% |
Stock Price Statistics
The stock price has increased by +9.65% in the last 52 weeks. The beta is 1.41, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | +9.65% |
| 50-Day Moving Average | 76.44 |
| 200-Day Moving Average | 68.79 |
| Relative Strength Index (RSI) | 64.79 |
| Average Volume (20 Days) | 5,322,475 |
Short Selling Information
The latest short interest is 17.55 million, so 4.65% of the outstanding shares have been sold short.
| Short Interest | 17.55M |
| Short Previous Month | 18.65M |
| Short % of Shares Out | 4.65% |
| Short % of Float | 4.67% |
| Short Ratio (days to cover) | 3.68 |
Income Statement
In the last 12 months, DexCom had revenue of $4.97 billion and earned $999.70 million in profits. Earnings per share was $2.54.
| Revenue | 4.97B |
| Gross Profit | 3.10B |
| Operating Income | 1.14B |
| Pretax Income | 1.28B |
| Net Income | 999.70M |
| EBITDA | 1.40B |
| EBIT | 1.14B |
| Earnings Per Share (EPS) | $2.54 |
Balance Sheet
The company has $1.95 billion in cash and $1.40 billion in debt, with a net cash position of $548.60 million or $1.45 per share.
| Cash & Cash Equivalents | 1.95B |
| Total Debt | 1.40B |
| Net Cash | 548.60M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 2.62B |
| Book Value Per Share | 6.95 |
| Working Capital | 1.73B |
Cash Flow
In the last 12 months, operating cash flow was $1.75 billion and capital expenditures -$343.70 million, giving a free cash flow of $1.41 billion.
| Operating Cash Flow | 1.75B |
| Capital Expenditures | -343.70M |
| Depreciation & Amortization | 264.10M |
| Net Borrowing | -1.21B |
| Free Cash Flow | 1.41B |
| FCF Per Share | $3.72 |
Margins
Gross margin is 62.47%, with operating and profit margins of 22.92% and 20.12%.
| Gross Margin | 62.47% |
| Operating Margin | 22.92% |
| Pretax Margin | 25.76% |
| Profit Margin | 20.12% |
| EBITDA Margin | 28.24% |
| EBIT Margin | 22.92% |
| FCF Margin | 28.27% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.61% |
| Shareholder Yield | 2.61% |
| Earnings Yield | 2.98% |
| FCF Yield | 4.19% |
Analyst Forecast
The average price target for DexCom is $94.12, which is 6.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $94.12 |
| Price Target Difference | 6.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 11.48% |
| EPS Growth Forecast (3Y) | 21.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 6.56 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.56 |
| Piotroski F-Score | 7 |